Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report

<p>Abstract</p> <p>Introduction</p> <p>Chondrosarcoma is well-known to be primarily resistant to conventional radiation and chemotherapy.</p> <p>Case presentation</p> <p>We present the case of a 32-year-old Caucasian man with clear cell chondrosarcoma who presented with symptomatic recurrence in his pelvis and metastases to his skull and lungs. Our patient underwent systemic therapy with sunitinib and then consolidation with proton beam radiation to his symptomatic site. He achieved complete symptomatic relief with a significantly improved performance status and had an almost complete and durable metabolic response on fluorine-18-fluorodeoxyglucose positron emission tomography.</p> <p>Conclusions</p> <p>Our findings have important clinical implications and suggest novel clinical trials for this difficult to treat disease.</p

Effect of replacing soybean meal with dried distillers grains in meat goat diets

Market goat nutrition has received limited attention and their requirements have often been extrapolated from other species (cattle and sheep) due to a lack of information. Specifically, there is very limited data available regarding the role of feeding dried distillers grains with solubles (DDGS) to goats. With the per protein unit cost advantage of DDGS over SBM being $1.86, DDGS would clearly price into goat diets as a protein source (October 26, 2017 U.S. Grains Council Report). However, there is insufficient data to base recommendations for potential inclusion of DDGS in a diet. Our objective is to evaluate the efficacy of DDGS as a replacement for SBM in a Boer goat diet. Forty-eight meat goat kids (approximately 70 d of age, initially 28.2kg) were used in a completely randomized design. Animals were housed at the Kansas State University Sheep and Meat Goat Center with 3 kids per pen (4 pens per treatment). Pens were allotted into one of four experimental diets: 1) 0% SBM replaced by DDGS; 2) 33% SBM replaced by DDGS; 3) 66% SBM replaced by DDGS; and 4) 100% SBM replaced by DDGS. All diets were pelleted at the Kansas State University feed mill with pellets formulated to contain roughage so no supplemental forage was needed. After a 14 day step up period, diets were fed for 46 days with goats and feeders weighed weekly to determine ADG, ADFI and G:F. Two goats per pen were randomly selected and slaughtered at a USDA-inspected facility with carcass data collected. Data was analyzed using the GLIMMIX procedure of SAS, with pen as the experimental unit and 0.05 as the alpha value. Dietary treatment increased (P0.10) due to a linear improvement (P0.10) on carcass measurements. In summary, including DDGS in replacement of SBM in Boer Goat diets did not impact ADG, ADFI or carcass measurements but did improve G:F

Combination therapy for renal cell cancer: what are possible options?

Antiangiogenic therapy has shown promise in the treatment of patients with renal cell carcinoma (RCC). Two classes of antiangiogenic drugs, the anti-vascular endothelial growth factor antibody bevacizumab and the tyrosine kinase inhibitors sorafenib, sunitinib and pazopanib, have shown efficacy in patients with RCC and are approved by the US Food and Drug Administration for treatment of this cancer. In practice, the clinical benefit of antiangiogenic drugs in RCC has been heterogeneous, and in patients who do respond, benefits are modest and/or short-lived. To improve efficacy, combination targeted therapy has been attempted, but with either very limited additional efficacy or nontolerable toxicities. Recent advances in the molecular understanding of tumor angiogenesis and mechanism of resistance, along with the rapid development of targeted drug discovery, have made it possible to further explore novel combination therapy for RCC